Aytu BioPharma (AYTU) vs Rockwell Medical (RMTI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Aytu BioPharma (AYTU) has outperformed Rockwell Medical (RMTI) over the past year, losing 13.5% versus a loss of 34.8%. Over five years, RMTI leads with a -88.0% price change compared with -96.1% for AYTU. Rockwell Medical is the larger company by market cap ($31.8 million vs $22.0 million), about 1.4 times the size.
On valuation, Aytu BioPharma trades at a lower forward P/E (13.1x vs 112.7x for Rockwell Medical).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AYTU | RMTI |
|---|---|---|
| Share price | $2.03 | $7.89 |
| Market cap | $22.01M | $31.80M |
| 1-day change | -1.22% | -1.62% |
| YTD return | -21.15% | -4.94% |
| 1-year return | -13.50% | -34.79% |
| 5-year return | -96.13% | -88.05% |
| Forward P/E | 13.06 | 112.71 |
| EPS (TTM) | $-1.16 | $-1.34 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.07 | $12.90 |
| 52-week low | $1.80 | $4.89 |
| Distance from 52-week high | -34.04% | -38.84% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +377.53% | +153.49% |
| Average volume | 34.22K | 26.44K |
| Shares outstanding | 10.87M | 4.03M |
| Employees | 75 | 157 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AYTU has outperformed RMTI by 21.3 percentage points over the past year.
About Aytu BioPharma
AYTU stock →Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT extended-release orally disintegrating tablets for patients from six years of age and above; Cotempla XR-ODT A central nervous system stimulant indicated for the treatment of ADHD in patients 6 to 17 years of age; and Metadate CD, a central nervous system stimulant indicated for the treatment of ADHD in patients 6 to 15 years of age.
Health Care · Biotechnology: Pharmaceutical Preparations · 75 employees
About Rockwell Medical
RMTI stock →Rockwell Medical, Inc., together with its subsidiaries, engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. It offers citrapure citric acid concentrate, dri-sate dry acid concentrate, renalpure liquid acid concentrate, dri-sate acid concentrate mixer, renalpure acid concentrate, renalpure bicarbonate concentrate, sterilyte bicarbonate concentrate, bicarbonate cartridges, and dry acid concentrate mixer, as well as ancillary products, including 5% acetic acid, cleaner, citric acid descaler, water softener salt pellets, and other supplies used by hemodialysis providers.
Health Care · Biotechnology: Pharmaceutical Preparations · 157 employees
AYTU vs RMTI FAQ
Which is bigger, Aytu BioPharma or Rockwell Medical?
Rockwell Medical (RMTI) is larger, with a market capitalization of $31.80M compared with $22.01M for Aytu BioPharma (AYTU).
Which stock has performed better over the past year, AYTU or RMTI?
AYTU returned -13.50% over the past 12 months, compared with -34.79% for RMTI (price return, excluding dividends). Past performance does not predict future results.
Are Aytu BioPharma and Rockwell Medical in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.